CANNTAB RECEIVES EXPORT LICENSE APPROVAL FROM HEALTH CANADA
TORONTO, March 30th, 2021/ – Canntab Therapeutics Limited (
CSE
ILL.CN) (
OTCQB:CTABF) (
FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.
Further to an announcement made on March 9, 2021, Canntab can now fulfill the purchase order received from Cann Global Limited (“Cann Global”). The initial purchase order of $406,200 with Cann Global includes 6 SKUs comprised of 2.5 mg THC, 5 mg THC, 12.5 mg CBD, 25 mg THC, and combined caplets (a hard coated tablet in the shape of a capsule) with 5 mg THC/25 mg CBD and 2.5 mg THC/12.5 mg CBD. The products ordered by Cann Global are expected to be distributed throughout Australia to medical distributors, including doctors, pharmacies, and hospitals.
Larry Latowsky, CEO of Canntab said “We are delighted to have received Health Canada’s export approval to enable us to meet our Australian partners’ orders in the immediate future. This is the first export order for us and we look forward to many more orders, not only from Cann Global, but from other international partners as they recognize the unique patented product offerings of Canntab. Our order to Australia also enables us to participate in one of the largest medical cannabis studies being conducted globally, and furthermore, we have engaged with Cann Global to begin the necessary work and development to undertake clinical blood studies specifically for measuring the efficacy of our immediate and extended-release products, which we hope to conclude by the end of the summer, our third quarter.”
